Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. (Q53191334)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 November 2011

Language	Label	Description	Also known as
English	Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.	scientific article published on 16 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

prostate cancer

1 reference

based on heuristic

inferred from title

Peter Bartenstein

11

object named as

Peter Bartenstein

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

8

object named as

Paul Cumming

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

12

object named as

Marcus Hacker

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Christopher Übleis

3

object named as

Christopher Ubleis

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

1

object named as

Vera Graute

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Markus Hartenbach

5

object named as

Markus Hartenbach

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Nathalie L Jansen

2

object named as

Nathalie Jansen

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

author name string

Michael Seitz

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Michael Karl Scherr

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Sven Thieme

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Katharina Klanke

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Reinhold Tiling

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

publication date

16 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

39

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

271-282

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Critical analysis of prostate-specific antigen doubling time calculation methodology

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Fluorocholine PET/CT in patients with prostate cancer: initial experience

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1970-2

21 January 2018

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates

1 reference

https://pubmed.ncbi.nlm.nih.gov/22086143

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-1970-2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22086143

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53191334&oldid=2212024902"